Mirabaud & Cie’s Novo Nordisk NVO Stock Holding History

Mirabaud & Cie’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$553K	Hold	14,600	–	–	0.21%	41
2026 Q2	$700K	Hold	14,600	–	–	0.28%	35
2026 Q1	$537K	Buy	14,600 +4,600	+46%	+$218K	0.22%	40
2025 Q4	$509K	Hold	10,000	–	–	0.16%	49
2025 Q3	$555K	Buy	10,000 +2,500	+33%	+$146K	0.18%	50
2025 Q2	$518K	Sell	7,500 -140	-2%	-$9.5K	0.16%	51
2025 Q1	$531K	Buy	+7,640	New	+$631K	0.18%	48

Other funds holding NVO

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Everett Harris & Co Los Angeles, California $8.46B AUM 13.48% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Saratoga Research & Investment Management Saratoga, California $1.82B AUM 11.8% 1-Year Est. Return

Markel Group Glen Allen, Virginia $12.8B AUM 8.77% 1-Year Est. Return

Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Oppenheimer Asset Management New York $9.5B AUM 23.46% 1-Year Est. Return

Mirabaud & Cie's NVO Position: Q3 2026 in Review

Mirabaud & Cie held its Novo Nordisk (NVO) position steady in Q3 2026 at 14,600 shares worth $553K. The position accounts for 0.21% of the portfolio, ranked #41.

Mirabaud & Cie first reported a position in NVO in Q1 2025 and has held it in 7 quarters since. The position peaked at $700K in Q2 2026. 696 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

Mirabaud & Cie held 14,600 shares of Novo Nordisk worth $553K as of Q3 2026.
Mirabaud & Cie left its Novo Nordisk share count unchanged in Q3 2026.
Novo Nordisk made up 0.21% of Mirabaud & Cie's portfolio in Q3 2026, its #41 holding.
Mirabaud & Cie first reported a position in Novo Nordisk in Q1 2025 and has held it in 7 quarters since.
Mirabaud & Cie's Novo Nordisk position peaked at $700K in Q2 2026.
696 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Mirabaud & Cie's 13F filing for Q3 2026, filed 27 Oct 2026.